15270876

Source:http://linkedlifedata.com/resource/pubmed/id/15270876

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0076080, umls-concept:C0278883, umls-concept:C0280209, umls-concept:C0441772, umls-concept:C1334080
pubmed:issue	1
pubmed:dateCreated	2004-7-23
pubmed:abstractText	A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0004041
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0007-0963
pubmed:author	pubmed-author:FiallaRR, pubmed-author:ForstingerChCh, pubmed-author:FritschPP, pubmed-author:Hofmann-WellenhofRR, pubmed-author:KehrerHH, pubmed-author:KernJJ, pubmed-author:Kindermann-GlebowskiEE, pubmed-author:KleinGG, pubmed-author:KohHH, pubmed-author:KollerJJ, pubmed-author:KonradKK, pubmed-author:LangAA, pubmed-author:MischerPP, pubmed-author:PachingerWW, pubmed-author:PehambergerHH, pubmed-author:RamaGG, pubmed-author:RatzingerGG, pubmed-author:RichtigEE, pubmed-author:SeeberAA, pubmed-author:SmolleJJ, pubmed-author:SteinerAA, pubmed-author:UlmerHH, pubmed-author:WolffKK, pubmed-author:ZelgerBB
pubmed:issnType	Print
pubmed:volume	151
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	91-8
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:15270876-Adult, pubmed-meshheading:15270876-Aged, pubmed-meshheading:15270876-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15270876-Dacarbazine, pubmed-meshheading:15270876-Drug Administration Schedule, pubmed-meshheading:15270876-Female, pubmed-meshheading:15270876-Follow-Up Studies, pubmed-meshheading:15270876-Humans, pubmed-meshheading:15270876-Interferon-alpha, pubmed-meshheading:15270876-Liver Neoplasms, pubmed-meshheading:15270876-Lung Neoplasms, pubmed-meshheading:15270876-Male, pubmed-meshheading:15270876-Melanoma, pubmed-meshheading:15270876-Middle Aged, pubmed-meshheading:15270876-Proportional Hazards Models, pubmed-meshheading:15270876-Recombinant Proteins, pubmed-meshheading:15270876-Remission Induction, pubmed-meshheading:15270876-Skin Neoplasms, pubmed-meshheading:15270876-Survival Rate
pubmed:year	2004
pubmed:articleTitle	Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
pubmed:affiliation	Department of Dermatology, University of Graz, Austria. erika.richtig@uni-graz.at
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study